Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    MRG-201
Previous Study | Return to List | Next Study

Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by miRagen Therapeutics, Inc.
Sponsor:
Information provided by (Responsible Party):
miRagen Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02603224
First received: November 9, 2015
Last updated: February 23, 2017
Last verified: October 2016
  Purpose

The primary objective of this study is to evaluate the safety and tolerability of the investigational drug, MRG-201, in healthy volunteers. MRG-201 is designed to mimic the activity of a molecule called miR-29 that decreases the expression of collagen and other proteins that are involved in scar formation. MRG-201 is being studied to determine if it can limit the formation of fibrous scar tissue in certain diseases.

MRG-201 will be tested in healthy volunteers by injection into intact skin or adjacent to a short skin incision. Volunteers may receive one or several doses of MRG-201, and will be monitored for local reactions in the skin, signs or symptoms of adverse effects on the body, and for the levels of MRG-201 in the blood over time. Skin biopsies will also be collected to study how cells in the skin respond when exposed to MRG-201.


Condition Intervention Phase
Healthy Volunteers
Drug: MRG-201
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of MRG-201 Following Local Intradermal Injection in Normal Healthy Volunteers

Further study details as provided by miRagen Therapeutics, Inc.:

Primary Outcome Measures:
  • Safety and tolerability of MRG-201 based on vital signs, physical examination, clinical laboratory tests, ECG, and incidence and severity of adverse events [ Time Frame: Up to 43 days ]

Secondary Outcome Measures:
  • Area under the plasma concentration vs. time curve (AUC) of MRG-201 following single and repeat doses [ Time Frame: Up to 17 days ]
  • Peak plasma concentration (Cmax) of MRG-201 following single and repeat doses [ Time Frame: Up to 17 days ]

Other Outcome Measures:
  • Exploratory assessment of the levels of miR-29 target mRNAs in skin following treatment with MRG-201 or placebo using the Nanostring nCounter® analysis system [ Time Frame: Up to 16 days ]

Estimated Enrollment: 70
Study Start Date: November 2015
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MRG-201 Drug: MRG-201
Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
Placebo Comparator: Placebo Drug: Placebo
Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.

Detailed Description:

Study Design:

Cohorts of 3-6 healthy male volunteers, ages 18-45, will receive single or multiple ascending doses of MRG-201 by intradermal injection at one site and placebo at a second site over a period of up to 15 days, with follow-up for up to 28 days after the last dose to determine the maximum tolerated dose in intact or incised normal skin and the tendency for active drug to diffuse through the skin.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males between 18 and 45 years of age inclusive
  • Body Mass Index (BMI) 18-35 kg/m^2 inclusive
  • Must have 2 regions on the lower back/upper buttocks free of striae, scars, tattoos or other skin pathologies
  • If engaged in sexual relations with a female of child-bearing potential, must be willing to use two effective contraceptive methods throughout the treatment period and for at least 12 weeks after the last treatment administration

Exclusion Criteria:

  • Clinically significant abnormalities in medical history or physical exam which in the opinion of the Investigator would make the subject unsuitable for inclusion in the study
  • History of cutaneous disorder that could interfere with the study or put the subject at risk
  • History of renal or liver dysfunction or evidence of renal or liver dysfunction at screening
  • History of clinically significant anemia or evidence of clinically significant anemia at screening
  • Positive for blood borne pathogen (HBV, HCV, HIV) at screening
  • Prior malignancies within the past 3 years (allowing squamous cell and basal cell carcinomas that have been successfully treated)
  • Use of systemic steroids or topical steroids on the target area within two months of the Baseline visit or use of topical steroids outside the target area within 14 days of the Baseline visit
  • Use of an investigational small molecule drug within 28 days of the baseline visit or use of an investigational oligonucleotide or biologic drug within 90 days of the baseline visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02603224

Contacts
Contact: miRagen Therapeutics, Inc. 720-407-4603

Locations
Canada, Quebec
Innovaderm Research, Inc. Recruiting
Montreal, Quebec, Canada, H2K 4L5
Contact: Valérie Bourdin    514-521-4285 ext 214      
Principal Investigator: Catherine Maari, MD         
Sponsors and Collaborators
miRagen Therapeutics, Inc.
Investigators
Study Director: Gilad S. Gordon, MD miRagen Therapeutics, Inc.
  More Information

Responsible Party: miRagen Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02603224     History of Changes
Other Study ID Numbers: MRG201-30-001
Study First Received: November 9, 2015
Last Updated: February 23, 2017

ClinicalTrials.gov processed this record on May 24, 2017